Charles River Laboratories International, Inc

Pharmaceuticals

CRL

$ 257 1.5

Share price

$ 13 bn

Market Cap

$ 16 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.24x the weighted average for S&P 500

FY2020

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Charles River Laboratories International, Inc reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 130 Kt (-4.8 /-3.6% y-o-y). Also positively, carbon intensity decreased to 45 t (-7 /-13.6% y-o-y).

Charles River Laboratories International, Inc's Scope 3 emissions increased to 312 Kt (+14/+4.8% y-o-y).

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2020Q4	130	90	41	312	2,924	45
2019Q4	135	93	42	297	2,621	52
2018Q4	170	92	84		2,266	75

Charles River Laboratories International, Inc

Carbon footprint

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Charles River Laboratories International, Inc's carbon footprint

Company environmental metrics